upadacitinib · Rinvoq

Small molecule

Also known as ABT-494

Approvedregulatory verdict

Evidence outlook

Approved: Atopic Dermatitis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis (label: moderately to severely active UC or CD who have had an inadequate response, lost response or were...), Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Lupus Erythematosus · Phase 3Vitiligo · Phase 3 · filing submittedHidradenitis Suppurativa · Phase 3Alopecia Areata · Phase 3 · filing submitted

Also approved (11)
US
  • Ankylosing Spondylitis RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.Outside this platform's coverage
  • Non-radiographic Axial Spondyloarthritis RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
  • Polyarticular Juvenile Idiopathic Arthritis RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
    Outside this platform's coverage
  • Giant Cell Arteritis RINVOQ is indicated for the treatment of adults with giant cell arteritis.Outside this platform's coverage
Product first approved 2019FDA label
EU
  • Severe alopecia areata in adults and adolescents 12 years and older (Rinvoq)news.abbvie.com
  • Marketing authorisation of Rinvoq (first indication RA); current EU label includes ulcerative colitis and Crohn's diseaseEMA
  • Non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy (Rinvoq)news.abbvie.com
Product first approved 2019
JP
  • Moderately to severely active Crohn's disease with inadequate response to existing therapykyodonewsprwire.jp
  • Moderately to severely active ulcerative colitis with inadequate response to existing therapykyodonewsprwire.jp
Product first approved 2022
UK
  • Moderately to severely active ulcerative colitis and Crohn's disease
Product first approved 2022medicines.org.uk
CA
  • Rheumatoid Arthritis RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. RINVOQ may be used as monotherapy or in combination with...
Product first approved 2019Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (47)
Alopecia Areata
NCT07772492 · AbbVie
2026-08-24 – 2032-03 · Severe Alopecia Areata
What this study did
Atopic Dermatitis
NCT06389136 · AbbVie
2024-06-14 – 2027-05 · Atopic Dermatitis
What this study did
NCT06390722 · AbbVie
2024-05-23 – 2026-07-08 · Atopic Dermatitis, Sleep Disturbance
What this study did
NCT04195698 · AbbVie
2020-01-15 – 2023-09-11 · Atopic Dermatitis
What this study did
NCT03738397 · AbbVie
2019-02-21 – 2020-12-09 · Atopic Dermatitis
What this study did
Crohn's Disease
NCT06332534 · AbbVie
2024-08-08 – 2031-01 · Crohn's Disease
What this study did
NCT06227910 · Takeda
2025-01-02 – 2028-08-01 · Crohn's Disease
What this study did
NCT07149467 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-09-10 – 2027-12-31 · Crohn's Disease Aggravated, Crohn's Disease in Remission
What this study did
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
NCT07008846 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-05-10 – 2026-09-30 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT05121298 · Atsushi Kawakami
2021-01-12 – 2024-09-30 · Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound, Biomarker
What this study did
Systemic Lupus Erythematosus
Ulcerative Colitis
NCT06660693 · McMaster University
2025-04-16 – 2027-09 · Colitis, Ulcerative
What this study did
NCT03006068 · AbbVie
2017-01-31 – 2027-07 · Ulcerative Colitis (UC)
What this study did
Vitiligo
NCT07896434 · AbbVie
2027-01-28 – 2032-08 · Non-Segmental Vitiligo
What this study did
NCT06118411 · AbbVie
2023-12-19 – 2028-03 · Vitiligo
What this study did
Other / comorbidity
NCT04161898 · AbbVie
2020-02-04 – 2028-08 · Takayasu Arteritis (TAK)
What this study did
NCT06928272 · Douglas D. Fraser
2025-09-10 – 2027-12 · Long COVID
What this study did
NCT03725202 · AbbVie
2019-01-24 – 2025-03-11 · Giant Cell Arteritis (GCA)
What this study did
NCT04169373 · AbbVie
2019-11-26 – 2025-02-28 · Spondyloarthritis
What this study did
NCT06758947 · Assiut University
2023-01-15 – 2024-11-15 · Interstitial Lung Disease Due to Systemic Disease (Disorder)
What this study did
Phase 2/3 (3)
Phase 2 (21)
Atopic Dermatitis
NCT07678645 · RenJi Hospital
2026-06-01 – 2028-05-31 · Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
What this study did
NCT02925117 · AbbVie
2016-10-25 – 2019-01-31 · Atopic Dermatitis
What this study did
Crohn's Disease
Hidradenitis Suppurativa
NCT07727889 · Peking Union Medical College
2026-07-01 – 2027-07-01 · Hidradenitis Suppurativa (Acne Inversa)
What this study did
Rheumatoid Arthritis
NCT02049138 · AbbVie
2014-01-24 – 2021-07-29 · Rheumatoid Arthritis
What this study did
NCT03823378 · AbbVie
2019-05-13 – 2020-09-09 · Rheumatoid Arthritis (RA)
What this study did
Systemic Lupus Erythematosus
Vitiligo
NCT04927975 · AbbVie
2021-06-30 – 2023-08-29 · Non-Segmental Vitiligo
What this study did
Other / comorbidity
NCT07588568 · University of North Carolina, Chapel Hill
2026-09-30 – 2030-06 · EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
What this study did
NCT07492251 · Centre Hospitalier Universitaire de Nice
2026-10-01 – 2028-11-01 · Lichen Penis Planus
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT07064889 · Peking University People's Hospital
2025-07-30 – 2027-12-30 · Immune Thrombocytopenia
What this study did
NCT06862284 · Peking University People's Hospital
2025-03-10 – 2027-08-31 · Primary Sjögren's Syndrome (pSS)
What this study did
NCT07080346 · Liu Tian
2024-01-25 – 2025-07-08 · Behcet Syndrome
What this study did
NCT03178487 · AbbVie
2017-10-24 – 2022-02-17 · Ankylosing Spondylitis (AS)
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07670156 · Lisa Satter
2026-12 – 2028-08 · JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
What this study did
NCT06873100 · Peking University People's Hospital
2024-11-15 – 2026-12-31 · Relapsing Polychondritis
What this study did
Phase 1 (8)
Atopic Dermatitis
NCT03646604 · AbbVie
2019-01-31 – 2024-08-29 · Atopic Dermatitis
What this study did
Crohn's Disease
NCT06902987 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-01-17 – 2026-12-30 · Crohn's Diseases, Active Anal Fistula, Upadacitinib
What this study did
Rheumatoid Arthritis
NCT01741493 · AbbVie (prior sponsor, Abbott)
2012-11 – 2013-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03725007 · AbbVie
2019-06-24 – 2029-03 · Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT06684522 · Northwestern University
2025-12-18 – 2027-06 · Eyelid Dermatitis
What this study did
NCT07843693 · AbbVie
2026-08-26 – 2026-12 · Healthy Volunteers
What this study did
NCT07425899 · AbbVie
2026-02-26 – 2026-06-05 · Healthy Volunteer
What this study did
NCT06379958 · Modern Biosciences Ltd
2024-04-08 – 2024-09-30 · Pharmacokinetics
What this study did
Phase 4 (19)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Crohn's Disease
NCT07510191 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-03-01 – 2029-12-31 · Crohn Disease (CD)
What this study did
NCT06520397 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-07-15 – 2027-07-31 · Crohn Disease
What this study did
Psoriatic Arthritis
NCT06454188 · CARE ARTHRITIS LTD.
2024-12-03 – 2028-10 · Psoriatic Arthritis, Spondyloarthritis, Axial
What this study did
Rheumatoid Arthritis
NCT06687551 · University Hospital, Toulouse
2025-06-06 – 2029-04-01 · Rheumatoid Arthritis (RA
What this study did
NCT07636057 · Sheikh Zayed Federal Postgraduate Medical Institute
2026-07-05 – 2027-05-10 · Rheumatoid Arthritis (RA)
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
Ulcerative Colitis
NCT07258771 · Berinstein, Jeffrey
2026-01-16 – 2030-12 · Ulcerative Colitis Acute
What this study did
NCT07700446 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2026-11-15 – 2030-04 · Ulcerative Colitis (UC)
What this study did
NCT07502339 · University of California, San Francisco
2026-10-15 – 2028-12-01 · UC - Ulcerative Colitis
What this study did
NCT07550673 · Xijing Hospital of Digestive Diseases
2026-04-20 – 2028-11-01 · Acute Severe Ulcerative Colitis
What this study did
NCT05867329 · Berinstein, Jeffrey
2023-09-30 – 2027-11 · Ulcerative Colitis Acute
What this study did
NCT07546097 · Yongquan Shi
2026-03-23 – 2027-06-30 · Acute Severe Ulcerative Colitis
What this study did
Other / comorbidity
NCT07770646 · The University of Texas Health Science Center, Houston
2026-11-01 – 2029-09-15 · Axial Spondyloarthritis (AxSpA)
What this study did
NCT07773623 · Tianjin Medical University
2025-01-01 – 2027-12-31 · Uveitis
What this study did
NCT07018206 · CARE ARTHRITIS LTD.
2026-05 – 2027-05 · Axial Spondylarthritis (axSpA)
What this study did
NCT06773403 · Psoriasis Treatment Center of Central New Jersey
2024-04-09 – 2025-06-06 · Prurigo Nodularis
What this study did
Early phase / not applicable (2)
Ulcerative Colitis
NCT06095596 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-11-01 – 2026-10-31 · Ulcerative Colitis (UC)
What this study did
Vitiligo
NCT06454461 · Jilin University
2024-12-04 – 2029-06-01 · Vitiligo
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Rheumatoid Arthritis
NCT07904754 · AbbVie
2026-12-07 – 2029-07 · Rheumatoid Arthritis
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Upadacitinib (Rinvoq): this drugApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Ivarmacitinib
Phase 3(overall)
Small moleculeJAK
not yet graded(overall)
No reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD0449
Phase 1(overall)
—JAK1
Partial signal(overall)
No reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
BMS-986454Phase 1—PAD4 (peptidylarginine deiminase 4)not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND261Phase 1Biologic (subtype unspecified)CD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND319Phase 1Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GSK5926371
Phase 1(overall)
Biologic (subtype unspecified)CD19 / CD20 (dual-antigen) with CD3 T-cell engagementnot yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication
SAR448501Phase 1Multispecific antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
UTAA91Phase 1Cell therapyCD19 (B cells) and PD-1+ pathogenic T cellsnot yet gradedNo reviewed efficacy summary in this indication
AB-101 (AlloNK)DiscontinuedCell therapyCell therapynot yet gradedNo reviewed efficacy summary in this indication
Londamocitinib
Discontinued
Small moleculeJAK1
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 73 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rinvoq (upadacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-12 · NCT07843693 · CT.gov ↗
What to watch
Phase 3Long COVIDRecruiting
Est. primary completion 2026-12 · NCT06928272 · CT.gov ↗
What to watch
Phase 2Primary Sjögren's Syndrome (pSS)Not yet recruiting
Est. primary completion 2026-12-30 · NCT06862284 · CT.gov ↗
What to watch
Phase 3Crohn's DiseaseNot yet recruiting
Est. primary completion 2026-12-31 · NCT07149467 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06520397 · CT.gov ↗
What to watch
2027 (15)
January 2027 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2027-01 · NCT06701331 · CT.gov ↗
What to watch
March 2027 (3)
Phase 3Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-03 · NCT05843643 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-03-05 · NCT07636057 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2027-03-30 · NCT07546097 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2027-05 · NCT06660693 · CT.gov ↗
What to watch
Phase 4Axial Spondylarthritis (axSpA)Not yet recruiting
Est. primary completion 2027-05 · NCT07018206 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Eyelid DermatitisRecruiting
Est. primary completion 2027-06 · NCT06684522 · CT.gov ↗
What to watch
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-06-08 · NCT06227910 · CT.gov ↗
What to watch
July 2027 (3)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-07 · NCT03006068 · CT.gov ↗
What to watch
Phase 2Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-07-01 · NCT07727889 · CT.gov ↗
What to watch
Phase 2Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2027-07-30 · NCT07064889 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-09 · NCT03345823 · CT.gov ↗
What to watch
November 2027 (2)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2027-11 · NCT05867329 · CT.gov ↗
What to watch
Phase 2Atopic DermatitisNot yet recruiting
Est. primary completion 2027-11-30 · NCT07678645 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4UveitisActive not recruiting
Est. primary completion 2027-12-31 · NCT07773623 · CT.gov ↗
What to watch
2028 (13)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3VitiligoActive not recruiting
Est. primary completion 2028-03 · NCT06118411 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2028-04-01 · NCT07550673 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Lichen Penis PlanusRecruiting
Est. primary completion 2028-05-01 · NCT07492251 · CT.gov ↗
What to watch
August 2028 (4)
Phase 1/2JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOFNot yet recruiting
Est. primary completion 2028-08 · NCT07670156 · CT.gov ↗
What to watch
Phase 3Takayasu Arteritis (TAK)Active not recruiting
Est. primary completion 2028-08 · NCT04161898 · CT.gov ↗
What to watch
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2028-08 · NCT05782907 · CT.gov ↗
What to watch
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2028-08 · NCT05889182 · CT.gov ↗
What to watch
September 2028 (2)
Phase 4Psoriatic ArthritisRecruiting
Est. primary completion 2028-09 · NCT06454188 · CT.gov ↗
What to watch
Phase 4Axial Spondyloarthritis (AxSpA)Not yet recruiting
Est. primary completion 2028-09-15 · NCT07770646 · CT.gov ↗
What to watch
December 2028 (3)
Phase 1Juvenile Idiopathic Arthritis (JIA)Active not recruiting
Est. primary completion 2028-12 · NCT03725007 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07502339 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07510191 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 3Alopecia AreataActive not recruiting
Est. primary completion 2029-02 · NCT07023302 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2029-04-01 · NCT06687551 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2029-06 · NCT05609630 · CT.gov ↗
What to watch
November 2029 (2)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2029-11 · NCT06461897 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2029-11 · NCT07700446 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2029-12 · NCT07258771 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 2EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)Recruiting
Est. primary completion 2030-02 · NCT07588568 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2030-04 · NCT06012240 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2031-01 · NCT06332534 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2032-03 · NCT07772492 · CT.gov ↗
What to watch
August 2032 (1)
Phase 3VitiligoNot yet recruiting
Est. primary completion 2032-08 · NCT07896434 · CT.gov ↗
What to watch
2035 (1)
June 2035 (1)
Phase 2/3Systemic SclerosisNot yet recruiting
Est. primary completion 2035-06 · NCT07933211 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026ApprovalEuropean Commission approves Rinvoq for polyarticular juvenile idiopathic arthritis
EU, EC · AbbVie · Source ↗
29 July 2026ApprovalEuropean Commission approves Rinvoq in severe alopecia areata
EU, EC · Source ↗
28 April 2026Filing submittedAbbVie submits a US application for upadacitinib (RINVOQ) in severe alopecia areata
US, FDA · AbbVie · Source ↗
3 February 2026Filing submittedAbbVie submits US and EU applications for upadacitinib (Rinvoq) in vitiligo
US, FDA · AbbVie · Source ↗
29 October 2025Topline resultTwo Phase 3 studies of upadacitinib in non-segmental vitiligo met their co-primary endpoints
AbbVie · Source ↗
13 October 2025ApprovalFDA approves updated RINVOQ indication for UC and Crohn's disease
US, FDA · Source ↗
21 August 2025Topline resultPhase 3 UP-AA Study 1 of upadacitinib in alopecia areata met its primary endpoint
AbbVie · Source ↗
30 July 2025Topline resultPhase 3 UP-AA Study 2 of upadacitinib in alopecia areata met its primary endpoint
AbbVie · Source ↗
29 April 2025ApprovalFDA approves RINVOQ for giant cell arteritis
US, FDA · Source ↗
8 April 2025ApprovalEC approves RINVOQ for giant cell arteritis
EU, EC · Source ↗